Joel represents start-up, emerging growth and mature life sciences companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries, as well as many of the most active venture capital funds and institutional investors in the sector. His practice spans the entire company lifecycle—from formation through late-stage financing and M&A—and he regularly serves as principal outside counsel on high-stakes partnering matters.​

Joel focuses on intellectual property–driven transactions, including complex collaborations, licenses and other “bet-the-company” strategic partnerships, as well as commercial contracts, financings and M&A. He frequently counsels life sciences companies on foundational platform and asset licenses, research, development and commercial collaborations, sponsored and collaborative research agreements, clinical trial agreements, and manufacturing, supply and distribution arrangements for cutting-edge therapeutics and technologies.

Joel has extensive experience negotiating with many of the world’s leading academic and research institutions, hospitals and non-profit research organizations, including Harvard, the Massachusetts Institute of Technology, the Broad Institute, the Wyss Institute, Massachusetts General Hospital, Brigham and Women’s Hospital, Howard Hughes Medical Institute, the Whitehead Institute, the University of Massachusetts, Dartmouth, Yale, the University of Pennsylvania, Johns Hopkins, Stanford, the University of California, Seattle Children’s Hospital, Boston Children’s Hospital, Cornell, Colorado State University, the University of Iowa, the University of Southern California and others. This experience allows him to efficiently navigate institutional policies and market positions to achieve practical and value‑creating outcomes for his clients.

Joel was recognized by LMG Life Sciences as the US Rising Star – Financial and Corporate in the 2025 Life Sciences Americas Awards, reflecting his growing reputation in the life sciences deal market.